Wednesday tips round-up: Ted Baker, Bellway, Oxford Instruments
16th Jun 2010 06:41
Fasion retailer Ted Baker's strong brand and distinctive product ranges appear to have lost none of their niche appeal. Neither does a share price of 510p, or 13 times earnings, look stretched for a company producing consistent double-digit profit growth, which has £15m of cash on its balance shee
Read moreFDA Releases First Set Of Drug, Biologic Safety Reviews
15th Jun 2010 20:33
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The Food and Drug Administration Tuesday released safety summaries of 26 recently approved products as part of a new initiative to formally track the safety of drugs and biologics after they are approved. Agency of
Read moreIN THE PIPELINE: Progress Seen In Battle Against Skin Cancer
15th Jun 2010 16:00
By Peter Loftus Of DOW JONES NEWSWIRES Recent research is raising hope that new drugs are on the horizon that could prolong the lives of people with the most serious form of skin cancer. The experimental drugs aren't cures, and the long-term prognosis for people with advanced melanoma ma
Read moreGlaxoSmithKline EC Grants Conditional Marketing OK For Votrient
15th Jun 2010 14:14
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a global healthcare group, said Tuesday that the European Commission or EC has granted a conditional marketing authorization for Votrient--pazopanib for the first-line treatment of advanced Renal Cell Carcinoma and for patients who have received prio
Read moreUPDATE: Genmab CEO Drakeman Steps Down, van de Winkel Named New CEO
15th Jun 2010 10:25
(Adds detail, analyst comment.) By Gustav Sandstrom Of DOW JONES NEWSWIRES Genmab AS (GEN.KO) said Tuesday its Chief Executive Lisa Drakeman is retiring from her position and will be replaced by Jan G.J. van de Winkel effective Tuesday, denting market speculation that partner GlaxoSmithK
Read moreMARKET TALK: Genmab CEO Shift Hints No Imminent GSK Bid
15th Jun 2010 09:42
0842 GMT [Dow Jones] Genmab's (GEN.KO) announcement that CEO Lisa Drakeman will be replaced Tuesday indicates a takeover bid from partner GlaxoSmithKline (GSK) is rather unlikely in the near future, says Sydbank analyst Rune Majlund Dahl. Says it would be unlikely to change CEO if company was soon t
Read moreStrides Arcolab Gets FDA OK For Sumatriptan Succinate Injection
14th Jun 2010 14:12
MUMBAI (Dow Jones)--Strides Arcolab Ltd. (532531.BY) said Monday it has received approval from the U.S. Food and Drug Administration to sell the generic sumatriptan succinate injection. Sumatriptan succinate, a copycat version of GlaxoSmithKline PLC's (GSK) Imitrex, is used to treat migraine.
Read moreMARKET TALK: Genmab Shrs Higher On Takeover Speculation
14th Jun 2010 09:31
0831 GMT [Dow Jones] Genmab (GEN.KO) shares +14% at DKK50.00 amid market speculation that partner GlaxoSmithKline (GSK) could place a bid for the company. An analyst says a takeover could be positive for the Danish biotech company, which has limited cash and might otherwise need to launch a rights i
Read moreGlaxoSmithKline: FDA Requests More Information About Booster Shot
11th Jun 2010 22:59
DOW JONES NEWSWIRES GlaxoSmithKline PLC (GSK, GSK.LN) said U.S. regulators have asked it to answer some questions about the company's proposed dual vaccine for two bacterial diseases before issuing an approval. The company said it received a complete response letter about the booster shot f
Read morePRESS RELEASE: Regulatory Update: GlaxoSmithKline Receives Complete Response from FDA for Candidate Meningococcal and Hib Combination Vaccine
11th Jun 2010 22:36
Regulatory Update: GlaxoSmithKline Receives Complete Response from FDA for Candidate Meningococcal and Hib Combination Vaccine GlaxoSmithKline [NYSE:GSK] announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the Biologics License App
Read moreN AMERICAN MORNING BRIEFING: Stocks Seen Little Changed
11th Jun 2010 11:25
DJIA Futures 10165.5 +10.5 +0.1% S&P 500 Futures 1082.3 +2.5 +0.2% Nasdaq Futures 1825.1 +4.0 +0.2% Above are as of 0615 ET FTSE 100 5175.2 +42.7 +0.8% Xetra DAX 6065.6 +9.0 +0.2% CAC40 3544.8 +28.1 +0.8% Above are as of 0
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
11th Jun 2010 07:33
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0633 GMT [Dow Jones] Barclays Capital upgrades GlaxoSmithKline (GSK) to overweight from equalweight, and keeps its price targ
Read moreMARKET TALK: BarCap Upgrades GlaxoSmithKline To Overweight
11th Jun 2010 07:33
0633 GMT [Dow Jones] Barclays Capital upgrades GlaxoSmithKline (GSK) to overweight from equalweight, and keeps its price target at 1380p. Says investor concerns around Avandia and Advair are overdone. Adds the stock seems cheap with a dividend yield of 6.2%, a free cashflow yield of 12%, and 17% ups
Read moreGlaxoSmithKline Buys Laboratorios Phoenix For $253M Cash
10th Jun 2010 16:11
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), said Thursday that it has acquired Laboratorios Phoenix S.A.C.yF, an Argentine pharmaceutical business, for a cash consideration of $253 million. "This is an important step forward in our strategy to grow our business in Latin America; a key grou
Read moreGlaxoSmithKline Says Partner HGSI Files Benlysta For US Approval
10th Jun 2010 12:45
By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--GlaxoSmithKline Plc (GSK) Thursday said partner Human Genome Sciences Inc. (HGSI) has applied for U.S. regulatory approval for their jointly-developed drug Benlysta, potentially the first new treatment in decades for the hard-to-trea
Read more